Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| Verapamil Only Product in Oral Dose FormNCT06483789 | HB BioTech, LLCPHASE2 | TERMINATED Decision to terminate study due to a lack of efficacy in this study population. There were no safety concerns identified that contributed to this decision. | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| Telmisartan Only Product in Oral Dose FormNCT06483789 | HB BioTech, LLCPHASE2 | TERMINATED Decision to terminate study due to a lack of efficacy in this study population. There were no safety concerns identified that contributed to this decision. | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| HB-1NCT06483789 | HB BioTech, LLCPHASE2 | TERMINATED Decision to terminate study due to a lack of efficacy in this study population. There were no safety concerns identified that contributed to this decision. | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| Enfortumab vedotinNCT05014139 | Astellas Pharma Global Development, Inc.PHASE1 | TERMINATED Trial was discontinued for strategic reasons. Decision was not based on safety concerns, futility, or request from regulatory authority, ethics committee, or institutional review board or EC/IRB. | Science15 SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| Ofloxacin otic solutionNCT03655665 | Boston Children's HospitalPHASE4 | TERMINATED There was limited enrollment in the study. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| ASP5502NCT06544642 | Astellas Pharma Global Development, Inc.PHASE1 | TERMINATED Company's strategic decision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| GemcitabineNCT04191135 | Merck Sharp & Dohme LLCPHASE2 | TERMINATED Business Reasons | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| CarboplatinNCT04191135 | Merck Sharp & Dohme LLCPHASE2 | TERMINATED Business Reasons | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| OlaparibNCT04191135 | Merck Sharp & Dohme LLCPHASE2 | TERMINATED Business Reasons | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| PembrolizumabNCT04191135 | Merck Sharp & Dohme LLCPHASE2 | TERMINATED Business Reasons | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| HB-201 IVNCT04630353 | AstraZenecaEARLY_PHASE1 | TERMINATED Sponsor decision. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| Batoclimab 340 mg SC bi-weeklyNCT05403541 | Immunovant Sciences GmbHPHASE3 | TERMINATED Sponsor Decision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| Matching Placebo SCNCT05403541 | Immunovant Sciences GmbHPHASE3 | TERMINATED Sponsor Decision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| Batoclimab 340 mg SC weeklyNCT05403541 | Immunovant Sciences GmbHPHASE3 | TERMINATED Sponsor Decision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| Batoclimab 680 mg SC weeklyNCT05403541 | Immunovant Sciences GmbHPHASE3 | TERMINATED Sponsor Decision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| SNG001NCT06999603 | Synairgen Research Ltd.PHASE2 | TERMINATED Study was stopped due to significantly low patient recruitment rate. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| LY4064912NCT07152002 | Eli Lilly and CompanyPHASE1 | TERMINATED Sponsor Decision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| NMRA-335140NCT06029439 | Neumora Therapeutics, Inc.PHASE3 | TERMINATED NMRA-335140 did not achieve the primary endpoint across three randomized controlled trials. Program discontinued due to lack of efficacy in MDD. | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| ARO-MUC5ACNCT05292950 | Arrowhead PharmaceuticalsPHASE1, PHASE2 | TERMINATED Sponsor business decision | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-14 |
| NivolumabNCT05904080 | National Cancer Institute (NCI)PHASE2 | SUSPENDED Scheduled Interim Monitoring | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| IpilimumabNCT05904080 | National Cancer Institute (NCI)PHASE2 | SUSPENDED Scheduled Interim Monitoring | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| Cabozantinib S-malateNCT05904080 | National Cancer Institute (NCI)PHASE2 | SUSPENDED Scheduled Interim Monitoring | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| CD70-targeted CAR-T cellsNCT07181720 | Chongqing Precision Biotech Co., LtdPHASE1 | SUSPENDED Sponsor stopped the study. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| PBANCT04041232 | Columbia UniversityEARLY_PHASE1 | SUSPENDED Administrative changes | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
| Lisocabtagene MaraleucelNCT07098364 | Fred Hutchinson Cancer CenterPHASE1, PHASE2 | SUSPENDED Insufficient funding | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-11 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |